Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01918254
Recruitment Status : Completed
First Posted : August 7, 2013
Last Update Posted : September 12, 2017
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche